ArticleImmunology2015
Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3⁺ regulatory T cells in skin-transplanted mice.
Article in Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- The role of IL-33/ST2 signaling in female reproductive diseases.Frontiers in cell and developmental biology · 2026Review
- Unlocking Transplant Tolerance with Biomaterials.Advanced healthcare materials · 2025Review
- Reduced autoimmunity associated with deletion of host CD73.ImmunoHorizons · 2025Article
- IL-33 Induces a Switch in Intestinal Metabolites Revealing the Tryptophan Pathway as a Target for Inducing Allograft Survival.Nutrients · 2024Article
- Innate immune cellular therapeutics in transplantation.Frontiers in transplantation · 2023Article
- Schizophrenia and Alarmins.Medicina (Kaunas, Lithuania) · 2022Review
- Aging Affects the Role of Myeloid-Derived Suppressor Cells in Alloimmunity.Frontiers in immunology · 2022Review
- Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD).Cellular immunology · 2021Article
- IL-33 drives the production of mouse regulatory T cells with enhanced in vivo suppressive activity in skin transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation.Frontiers in immunology · 2021Review
- Untangling Local Pro-Inflammatory, Reparative, and Regulatory Damage-Associated Molecular-Patterns (DAMPs) Pathways to Improve Transplant Outcomes.Frontiers in immunology · 2021Review
- Integration of Islet/Beta-Cell Transplants with Host Tissue Using Biomaterial Platforms.Endocrinology · 2020Review
- Dynamic changes in the regulatory T-cell heterogeneity and function by murine IL-2 mutein.Life science alliance · 2020Article
- Regulatory T cell adaptation in the intestine and skin.Nature immunology · 2019Review
- IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis.Cellular & molecular immunology · 2019Article
- Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation.Frontiers in immunology · 2019Review
- Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation.International journal of molecular sciences · 2018Review
- Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis.Archives of dermatological research · 2018Article
- Evaluation of biomaterial scaffold delivery of IL-33 as a localized immunomodulatory agent to support cell transplantation in adipose tissue.Journal of immunology and regenerative medicine · 2018Article
- Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy.Journal of translational medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-33 (IL-33) has been a focus of study because of its variety of functions shaping CD4(+) T-cell biology. In the present work, we evaluated the modulatory effect of IL-33 on suppressor cells in an in vivo transplantation model. C57BL/6 wild-type mice were grafted with syngeneic or allogeneic skin transplants and treated with exogenous IL-33 daily. After 10 days of treatment, we analysed draining lymph node cellularity and found in allogeneic animals an increment in myeloid-derived suppressor cells, which co-express MHC-II, and become enriched upon IL-33 treatment. In line with this observation, inducible nitric oxide synthase and arginase 1 expression were also increased in allogeneic animals upon IL-33 administration. In addition, IL-33 treatment up-regulated the number of Foxp3(+) regulatory T (Treg) cells in the allogeneic group, complementing the healthier integrity of the allografts and the increased allograft survival. Moreover, we demonstrate that IL-33 promotes CD4(+) T-cell expansion and conversion of CD4(+) Foxp3(-) T cells into CD4(+) Foxp3(+) Treg cells in the periphery. Lastly, the cytokine pattern of ex vivo-stimulated draining lymph nodes indicates that IL-33 dampens interferon-γ and IL-17 production, stimulating IL-10 secretion. Altogether, our work complements previous studies on the immune-modulatory activity of IL-33, showing that this cytokine affects myeloid-derived suppressor cells at the cell number and gene expression levels. More importantly, our research demonstrates for the first time that IL-33 allows for in vivo Foxp3(+) Treg cell conversion and favours an anti-inflammatory or tolerogenic state by skewing cytokine production. Therefore, our data suggest a potential use of IL-33 to prevent allograft rejection, bringing new therapeutics to the transplantation field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.